Drug Trial Radar · NCT06545331
Study of XB010 in Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Aug 6, 2024
Primary completion
Nov 23, 2026
Study completion Oct 20, 2027
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Conditions
- Locally Advanced or Metastatic Solid Tumors
- Esophageal Squamous Cell Cancer
- Head and Neck Squamous Cell Cancer
- NSCLC (Non-small Cell Lung Cancer)
- Hormone-receptor-positive Breast Cancer
- Triple Negative Breast Cancer (TNBC)
Interventions
XB010Drug
IV administration of XB010
PembrolizumabDrug
IV administration of Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010Time frame: 18 months
- Dose-Escalation Stage: Safety of XB010Time frame: 18 months
- Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]Time frame: 18 months
- Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]Time frame: 18 months
- Cohort-Expansion Stage: Preliminary antitumor activity of XB010Time frame: 24 months
Locations
20 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California · Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia · Completed
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida · Recruiting
Winship Cancer Institute
Atlanta, Georgia · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
Montefiore Medical Center - Montefiore Medical Park
The Bronx, New York · Recruiting
Carolina BioOncology Institute
Huntersville, North Carolina · Completed
Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
NEXT Austin
Austin, Texas · Recruiting
Baylor University Medical Center
Dallas, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Inova Schar Cancer
Fairfax, Virginia · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom · Recruiting
Sarah Cannon Research Institute London
London, United Kingdom · Recruiting
University College London Hospitals NHS Foundation Trust
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.